Rome Sentinel3 小时
New York Among Minority of States Where Medicaid Doesn't Cover Obesity-Indicated GLP-1s
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
TiogaPublishing.com20 小时
Pennsylvania Medicaid Spent $297.8M on GLP-1s for Obesity Over the Past 12 Months
The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...
Tyler Morning Telegraph3 小时
Medicaid Now Covers GLP-1s for Obesity in Texas
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Mountain Democrat2 小时
California Medicaid Spent $1.4B on GLP-1s for Obesity Over the Past 12 Months
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Frontiers20 小时
4Rs in Ethnopharmacology - Reduce, Refine, Replace and Responsibility using Animal Models
You will be redirected to our submission process. This Research Topic provides a comprehensive exploration into the practice and implications of the 4R principals in ethnopharmacology: Reduce, Refine, ...